A clinical-stage biotechnology company developing a novel and distinct approach to biologically repairing damaged and diseased tissues and organs affected by various diseases and serious conditions - only marginally SBIR involved - Angiocrine is creating a pipeline of Advanced Reparative Medicines clinically applicable to multiple conditions with significant unmet medical need. Grounded in the firm's E-CEL® Platform. the firm develops research and therapeutic products based on stem cell- and endothelial cell-related technologies. The firm's core technology is licensed from Weill Cornell Medical College and was invented and developed by the company's founder, Professor Shahin Rafii, M.D. The primary technology is E-CEL™ Technology, comprises cultured endothelial cells, genetically modified via insertion of the adenovirus E4ORF1 gene. The company is pursuing additional therapies based on its proprietary genetically engineered E-CEL Technology Platform with potential applications in cellular immunotherapy for hematologic cancers, cellular regenerative medicine, and hematopoietic stem cell gene therap
